Boekel, L, Atiqi, S, Leeuw, M, Hooijberg, F, Besten, Y R, Wartena, R, Steenhuis, M, Vogelzang, E, Webers, C, Boonen, A, Gerritsen, M, Lems, W F, Tas, S W, van Vollenhoven, R F, Voskuyl, A E, van der Horst-Bruinsma, I, Nurmohamed, M, Rispens, T & Wolbink, G 2023, ' Post-COVID condition in patients with inflammatory rheumatic diseases : a prospective cohort study in the Netherlands ', The Lancet Rheumatology, vol. 5, no. 7, pp. e375-e385 . https://doi.org/10.1016/S2665-9913(23)00127-3
The Lancet Rheumatology, 4(11), e747-e750. Lancet Publishing Group Boekel, L, Besten, Y R, Hooijberg, F, Wartena, R, Steenhuis, M, Vogelzang, E, Leeuw, M, Atiqi, S, Tas, S W, Lems, W F, van Ham, S M, Eftimov, F, Stalman, E W, Wieske, L, Kuijpers, T W, Voskuyl, A E, van Vollenhoven, R F, Gerritsen, M, Krieckaert, C, Rispens, T, Boers, M, Nurmohamed, M T & Wolbink, G 2022, ' SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period ', The Lancet Rheumatology, vol. 4, no. 11, pp. e747-e750 . https://doi.org/10.1016/S2665-9913(22)00221-1 The Lancet. Rheumatology, 4(11), e747-e750
The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group The Lancet. Rheumatology, 4, e417-e429 T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3 The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER The Lancet. Rheumatology, 4, 6, pp. e417-e429 The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd The Lancet Rheumatology, 4(6), e417-e429. Elsevier